Max Sung is an Oncology physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 131 publications with 6,688 citations (h-index 35); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Mount Sinai Hospital-Ruttenberg Treatment Center
1190 5th Avenue Guggenheim Pavill
New York, NY 10029
Telephone
212-241-6756Registry record last updated 30 Aug 2012.
Clinical trials
- Gene Therapy in Treating Women With Metastatic Breast Cancer
Sponsor: Max Sung
- Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Sponsor: Icahn School of Medicine at Mount Sinai
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20257 payments
- GlaxoSmithKline, LLC.Program year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 1998–2009 per NIH RePORTER. The latest:
- CLINICAL TRIAL: ADENOVIRAL VECTOR DELIVERY OF THE HUMAN INTERLEUKIN-12 CDNA IN M
Icahn School of Medicine at Mount Sinai
FY2009$25,691M01RR000071 - CLINICAL TRIAL: ADENOVIRAL VECTOR DELIVERY OF THE HUMAN INTERLEUKIN-12 CDNA IN M
Icahn School of Medicine at Mount Sinai
FY2008$21,688M01RR000071 - TRIAL OF HUMAN INTERLEUKIN-12 CDNA IN METASTATIC COLORECTAL CANCER TO THE LIVER
Icahn School of Medicine at Mount Sinai
FY2007$82,669M01RR000071
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
The Lancet. Gastroenterology & hepatology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”